Enveda Therapeutics, a Colorado-based startup specializing in artificial intelligence for drug discovery, has successfully raised $130 million in a Series C funding round. This investment, led by Kinnevik and FPV Ventures, follows a previous $55 million raised in June. The funding will support Enveda's ongoing efforts to develop new drug candidates, including the launch of a Phase I clinical trial for an oral eczema treatment. The company has made significant strides in just five years, transitioning from pre-seed funding to clinical-stage programs, and aims to leverage AI to accelerate the discovery of breakthrough medicines.